The global schizophrenia drugs market size was valued at USD 8.70 billion in 2024. It is projected to grow from USD 9.08 billion in 2025 to USD 12.29 billion by 2032, exhibiting a CAGR of 4.4% during the forecast period. North America dominated the schizophrenia drugs market with a market share of 62.87% in 2024.
Continue reading for more details:
https://www.fortunebusinessinsights.com/industry-reports/schizophrenia-drugs-market-101531
Market Segmentation
- By Drug Class: Includes typical antipsychotics, atypical antipsychotics, and others targeting various neurotransmitter pathways.
- By Therapeutic Type: Consists of first-generation, second-generation, and third-generation therapies used for short-term and maintenance treatment.
- By Route of Administration: Segmented into oral, injectable, and transdermal formulations to improve patient compliance.
- By Distribution Channel: Covers hospital pharmacies, retail pharmacies, and online pharmacies, reflecting diverse access preferences across the Schizophrenia Drugs Market.
- By End User: Includes hospitals, psychiatric clinics, and home care settings, driven by growing mental health awareness and treatment accessibility.
List Of Key Companies Profiled
- H. Lundbeck A/S
- Otsuka Pharmaceutical Co., Ltd.
- Janssen Pharmaceuticals, Inc.
- Eli Lilly and Company
- AstraZeneca
- ALLERGAN
- Vanda Pharmaceuticals Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
- Alkermes plc